An experimental model of murine chromoblastomycosis and in
vitro tests with Fonsecaea pedrosoi were used to test
the sensitivity of this fungus to three different
antimycotics. The experimental model was standardized in
BALB/c mice inoculated intraperitoneally with a 10^6 CFU/ml
suspension of a F. pedrosoi isolate. Clinical infection
was evident after 5 days of inoculation. Three groups of 27
mice each were used in the experiment. One group was treated
with ketoconazole (KTZ), another with itraconazole (ITZ) and
the other with saperconazole (SPZ). Antimycotic therapy was
continued for 21 days. The control group consisted of 40 mice
which were inoculated, but not treated. Infection was
documented by macroscopic and microscopic examination of
affected tissue in addition to culture of tissue macerates.
Minimal inhibitory concentrations (MIC) and minimal fungicidal
concentrations (MFC) for the F. pedrosoi strain used
were done. The in vitro results showed that SPZ was the most
active with MIC 0.01 mg/ml and MFC 0.1 mg/ml, followed by ITZ.
SPZ was also the most effective in vivo since 63% of
the treated animals (p=0.01) showed a curative effect after
the observation period. We concluded that SPZ had the best in
vitro and in vivo activity against F. pedrosoi.